SG11201803642WA - Bacteria-based protein delivery - Google Patents

Bacteria-based protein delivery

Info

Publication number
SG11201803642WA
SG11201803642WA SG11201803642WA SG11201803642WA SG11201803642WA SG 11201803642W A SG11201803642W A SG 11201803642WA SG 11201803642W A SG11201803642W A SG 11201803642WA SG 11201803642W A SG11201803642W A SG 11201803642WA SG 11201803642W A SG11201803642W A SG 11201803642WA
Authority
SG
Singapore
Prior art keywords
international
basel
rule
november
domains
Prior art date
Application number
SG11201803642WA
Other languages
English (en)
Inventor
Simon Ittig
Marlise Amstutz
Christoph Kasper
Original Assignee
Univ Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Basel filed Critical Univ Basel
Publication of SG11201803642WA publication Critical patent/SG11201803642WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201803642WA 2015-11-19 2016-11-17 Bacteria-based protein delivery SG11201803642WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15195493 2015-11-19
PCT/EP2016/078087 WO2017085235A1 (en) 2015-11-19 2016-11-17 Bacteria-based protein delivery

Publications (1)

Publication Number Publication Date
SG11201803642WA true SG11201803642WA (en) 2018-06-28

Family

ID=54697465

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803642WA SG11201803642WA (en) 2015-11-19 2016-11-17 Bacteria-based protein delivery

Country Status (24)

Country Link
US (1) US11702663B2 (el)
EP (1) EP3377634B1 (el)
JP (1) JP6937752B2 (el)
KR (1) KR20180081798A (el)
CN (1) CN108884466B (el)
AU (1) AU2016355975B2 (el)
BR (1) BR112018009782A8 (el)
CA (1) CA3005380A1 (el)
CY (1) CY1123654T1 (el)
DK (1) DK3377634T3 (el)
EA (1) EA039922B1 (el)
ES (1) ES2830251T3 (el)
HK (1) HK1256138A1 (el)
HR (1) HRP20201792T1 (el)
HU (1) HUE051184T2 (el)
IL (1) IL259050B2 (el)
LT (1) LT3377634T (el)
PL (1) PL3377634T3 (el)
PT (1) PT3377634T (el)
RS (1) RS61046B1 (el)
SG (1) SG11201803642WA (el)
SI (1) SI3377634T1 (el)
WO (1) WO2017085235A1 (el)
ZA (1) ZA201803901B (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014071182A1 (en) 2012-11-01 2014-05-08 Massachusetts Institute Of Technology Directed evolution of synthetic gene cluster
CN115960919A (zh) * 2014-05-21 2023-04-14 巴塞尔大学 基于细菌的蛋白质递送
RU2769873C2 (ru) 2015-07-13 2022-04-07 Пивот Байо, Инк. Способы и композиции для улучшения признаков растений
AU2016358257B2 (en) 2015-11-19 2023-08-17 Universitat Basel Virulence attenuated bacteria for treatment of malignant solid tumors
PT3559022T (pt) 2016-12-20 2021-08-19 Univ Basel Distribuição de proteínas baseada em bactérias com virulência atenuada
CN111587287A (zh) 2017-10-25 2020-08-25 皮沃特生物股份有限公司 用于改良固氮的工程微生物的方法和组合物
WO2022087856A1 (zh) * 2020-10-26 2022-05-05 南京吉芮康生物科技研究院有限公司 一种减毒沙门氏菌分泌表达rbd结构域蛋白的新型冠状病毒疫苗抗原递呈系统及其应用
KR20230098197A (ko) * 2020-10-27 2023-07-03 티3 파마슈티컬스 아게 세균 기반한 단백질 전달
CN117440829A (zh) * 2021-03-25 2024-01-23 T3制药股份公司 用于治疗癌症的药物组合
CN117362451B (zh) * 2023-12-04 2024-03-08 北京质肽生物医药科技有限公司 一种包含tev蛋白酶的融合蛋白、制备方法及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965381A (en) * 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
WO2000002996A2 (en) * 1998-07-10 2000-01-20 Cornell Research Foundation, Inc. Recombinant constructs and systems for secretion of proteins via type iii secretion systems
WO2002026819A2 (en) 2000-09-26 2002-04-04 Roger Williams Hospital Recombinant bcg vaccines for the prevention and treatment of cancer
WO2002077249A2 (en) * 2001-03-26 2002-10-03 Universite Catholique De Louvain Type iii bacterial strains for use in medicine
FR2862312B1 (fr) * 2003-11-13 2006-02-17 Univ Grenoble 1 Outil de transfert et de production de proteines mettant en oeuvre le systeme de secretion de type iii de pseudomonas
EP1661912A1 (en) * 2004-11-29 2006-05-31 Xigen S.A. Fusion protein comprising a BH3-domain of a BH3-only protein
JP2009510169A (ja) 2005-10-04 2009-03-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 細菌抗原送達系を用いた免疫応答を刺激するための方法
WO2008019183A2 (en) * 2006-05-18 2008-02-14 The Regents Of The University Of California Biopolymer and protein production using type iii secretion systems of gram negative bacteria
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
AU2009226972B2 (en) 2008-03-17 2014-05-29 Gerhard Heusipp YopM as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions
CN113563478A (zh) * 2013-09-24 2021-10-29 梅迪塞纳医疗股份有限公司 白介素-4受体结合融合蛋白及其应用
US10143743B2 (en) * 2013-11-18 2018-12-04 Yale University Non-replicating bacterial nanoparticle delivery system and methods of use
CN115960919A (zh) * 2014-05-21 2023-04-14 巴塞尔大学 基于细菌的蛋白质递送
AU2016358257B2 (en) 2015-11-19 2023-08-17 Universitat Basel Virulence attenuated bacteria for treatment of malignant solid tumors
PT3559022T (pt) 2016-12-20 2021-08-19 Univ Basel Distribuição de proteínas baseada em bactérias com virulência atenuada

Also Published As

Publication number Publication date
EP3377634B1 (en) 2020-08-12
LT3377634T (lt) 2020-12-28
HK1256138A1 (zh) 2019-09-13
CN108884466B (zh) 2022-06-03
US20190194670A1 (en) 2019-06-27
EP3377634A1 (en) 2018-09-26
AU2016355975B2 (en) 2022-12-08
CA3005380A1 (en) 2017-05-26
BR112018009782A2 (pt) 2018-11-06
ES2830251T3 (es) 2021-06-03
DK3377634T3 (da) 2020-11-16
SI3377634T1 (sl) 2021-01-29
IL259050B2 (en) 2024-03-01
US11702663B2 (en) 2023-07-18
AU2016355975A1 (en) 2018-05-10
HRP20201792T1 (hr) 2020-12-25
PT3377634T (pt) 2020-11-16
EA201890914A1 (ru) 2018-12-28
JP6937752B2 (ja) 2021-09-22
ZA201803901B (en) 2019-04-24
IL259050A (en) 2018-07-31
CY1123654T1 (el) 2022-03-24
HUE051184T2 (hu) 2021-03-01
JP2019500027A (ja) 2019-01-10
WO2017085235A1 (en) 2017-05-26
RS61046B1 (sr) 2020-12-31
BR112018009782A8 (pt) 2019-02-26
EA039922B1 (ru) 2022-03-28
KR20180081798A (ko) 2018-07-17
PL3377634T3 (pl) 2021-03-08
IL259050B1 (en) 2023-11-01
CN108884466A (zh) 2018-11-23

Similar Documents

Publication Publication Date Title
SG11201803642WA (en) Bacteria-based protein delivery
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201908540PA (en) Stable antibody formulation
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201811432WA (en) Rna for cancer therapy
SG11201901206SA (en) Trimer stabilizing hiv envelope protein mutations
SG11201903928WA (en) Mesenchymal stem cells populations, their products, and use thereof
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201909949XA (en) Targeted immunotolerance
SG11201807912SA (en) Vaccine against rsv
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201804070XA (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201909011PA (en) Niraparib compositions
SG11201811363YA (en) Anti-zika virus antibodies and methods of use
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201407343XA (en) Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
SG11201408174UA (en) Antibody formulation
SG11201408051VA (en) Cho expression system
SG11201407866XA (en) Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity